All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CBP-307
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2020
Details:
Novel, next-generation S1P1 agonist currently in Phase 2 clinical development for treatment of inflammatory bowel disease.